RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 301–400 of 764
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 30
Ethanol stimulates epithelial sodium channels by elevating reactive oxygen species
Bao, H., Song, J. Z., Duke, B. J., Ma, H., Denson, D. D., & Eaton, D. C. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00139.2012 · Cited by 24
Protein Homeostasis Networks and the Use of Yeast to Guide Interventions in Alzheimer’s Disease
Dhakal, S., & Macreadie, I. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218014 · Cited by 28
Simmons, B. H., Lee, J. H., Lalwani, K., Giddabasappa, A., Snider, B. A., Wong, A., Lappin, P. B., Eswaraka, J. R., Kan, J. L. C., Christensen, J. G., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1899-6 · Cited by 24
Yan, B., Zhao, D., Yao, Y., Bao, Z., Lu, G., & Zhou, J. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14773 · Cited by 24
“H-Ras belongs to the RAS family of GTPases and contributes to numerous cellular functions including control of cell apoptosis and proliferation[18].”
BackgroundGrzes, M., Oroń, M., Staszczak, Z., Jaiswar, A., Nowak-Niezgoda, M., & Walerych, D. (2020) · Cancers · doi:10.3390/cancers12061532 · Cited by 26
The G-Protein Rab5A Activates VPS34 Complex II, a Class III PI3K, by a Dual Regulatory Mechanism
Buckles, T. C., Ohashi, Y., Tremel, S., McLaughlin, S. H., Pardon, E., Steyaert, J., Gordon, M. T., Williams, R. L., & Falke, J. J. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.10.028 · Cited by 30
Harada, A., Matsumoto, S., Yasumizu, Y., Shojima, K., Akama, T., Eguchi, H., & Kikuchi, A. (2021) · eLife · doi:10.7554/elife.66721 · Cited by 27
“Because PI3 kinase is one of the direct effector proteins of RAS (Castellano and Downward, 2011; Rodriguez- Viciana et al., 1994), RAS- dependent PI3 kinase activation and ARL4C expression could co- operatively function to promote pancreatic cancer invasion.”
BackgroundClinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer.
Tai, C.-J., Chang, C.-C., Jiang, M.-C., Yeh, C., Su, T., Wu, P.-R., Chen, C., Yeh, K.-T., Lin, S.-H., & Chen, H.-C. (2012) · PubMed · Cited by 25
Baskar, R., Yap, S. P., Chua, K. L. M., & Itahana, K. (2012) · Europe PMC (PubMed Central) · Cited by 48
Weingaertner, I. R., Koutnik, S., & Ammer, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053510 · Cited by 24
“Although we cannot exclude such a mechanism, our results suggest that PI3K contributes to the Heregulin-induced cleavage of EGF-like ligands by metalloproteinase.”
BackgroundInfluentialKu, B. M., Jho, E. H., Bae, Y.-H., Sun, J., Ahn, J. S., Park, K., & Ahn, M. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0163-9 · Cited by 26
Ghosh, A., Lai, C. S. L., McDonald, S., Suraweera, N., Sengupta, N., PROPPER, D. J., Dorudi, S., & Silver, A. R. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.09.001 · Cited by 25
CUT Domain Proteins in DNA Repair and Cancer
Ramdzan, Z. M., Vickridge, E., Faraco, C. C. F., & Nepveu, A. (2021) · Cancers · doi:10.3390/cancers13122953 · Cited by 26
Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer
Hashemi, M., Khosroshahi, E. M., Asadi, S., Tanha, M., Mohseni, F. G., Sagha, R. A., Taheri, E., Vazayefi, P., Shekarriz, H., Habibi, F., et al. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.08.002 · Cited by 30
“Cross-talk between the PI3K/Akt and RAS/ERK pathways is essential for regulating cell growth and survival [36].”
BackgroundThe RAS subfamily Evolution – tracing evolution for its utmost exploitation
Saad, I. I., Saha, S. B., & Thomas, G. (2014) · Bioinformation · doi:10.6026/97320630010293 · Cited by 27
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
Visentin, A., Frezzato, F., Severin, F., Imbergamo, S., Pravato, S., Gargarella, L. R., Manni, S., Pizzo, S., Ruggieri, E., Facco, M., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s268899 · Cited by 24
Adariani, S. R., Jasemi, N. S. K., Bazgir, F., Wittich, C., Amin, E., Seidel, C. A. M., Dvorský, R., & Ahmadian, M. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100626 · Cited by 25
“PI3Kα generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and regulates cell growth, cell survival, cytoskeleton reorganization, and metabolism (36).”
BackgroundInfrequent RAS mutation is not associated with specific histological phenotype in gliomas
Makino, Y., Arakawa, Y., Yoshioka, E., Shofuda, T., Minamiguchi, S., Kawauchi, T., Tanji, M., Kanematsu, D., Nonaka, M., Okita, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08733-4 · Cited by 25
“Meanwhile, dysregulations in the p53, RB1, and MAPK and/or PI3K pathways are involved in the molecular pathogenesis of glioblastoma.”
BackgroundInfluentialSignal Transduction Regulators in Axonal Regeneration
Hausott, B., Glueckert, R., Schrott‐Fischer, A., & Klimaschewski, L. P. (2022) · Cells · doi:10.3390/cells11091537 · Cited by 26
Koushik, A. B., Welter, B. H., Rock, M. L., & Temesvari, L. A. (2014) · Eukaryotic Cell · doi:10.1128/ec.00329-13 · Cited by 27
A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Galbán, S., Apfelbaum, A. A., Espinoza, C. E., Heist, K., Haley, H. R., Bedi, K., Ljungman, M. E., Galbán, C. J., Luker, G. D., Dort, M. V., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0207 · Cited by 22
Ding, J., Zhang, L., Zeng, S., & Feng, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.082 · Cited by 23
Hong, S., Jeong, J. H., Chan, A. M.-L., & Park, J. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.05.008 · Cited by 22
Lim, C., Xu, J.-C., Chen, T., Xu, J., Chen, W., Hu, J., Li, Q., & Zhang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1137-y · Cited by 23
Djuzenova, C. S., Fiedler, V., Katzer, A., Michel, K., Deckert, S., Zimmermann, H., Sukhorukov, V. L., & Flentje, M. P. (2016) · Oncotarget · doi:10.18632/oncotarget.9501 · Cited by 23
“The most probable explanation for this result is that SW480 cells contain a mutation in kRas, which is directly implicated in the ERK signaling axis as well as in the PI3K pathway [22].”
BackgroundHigh-Temperature Requirement A 1 Causes Photoreceptor Cell Death in Zebrafish Disease Models
Oura, Y., Nakamura, M., Takigawa, T., Fukushima, Y., Wakabayashi, T., Tsujikawa, M., & Nishida, K. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.08.012 · Cited by 24
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses
Akan, D. T., Howes, J. E., Sai, J., Arnold, A. L., Beesetty, Y., Phan, J., Olejniczak, E. T., Waterson, A. G., & Fesik, S. W. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00869 · Cited by 22
High PYGL Expression Predicts Poor Prognosis in Human Gliomas
Zhao, C., Hua, C.-H., Li, C., Zheng, R., & Li, X. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.652931 · Cited by 23
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 26
Sumisławski, P., Rotermund, R., Klose, S., Lautenbach, A., Wefers, A. K., Soltwedel, C., Mohammadi, B., Jacobsen, F., Mawrin, C., Flitsch, J., et al. (2022) · Endocrine · doi:10.1007/s12020-021-02954-0 · Cited by 23
Regulation of GTPase function by autophosphorylation
Johnson, C. W., Seo, H., Terrell, E. M., Yang, M.-H., KleinJan, F., Gebregiworgis, T., Gasmi-Seabrook, G. M. C., Geffken, E. A., Lakhani, J., Song, K., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.011 · Cited by 22
Steinestel, K., Brüderlein, S., Steinestel, J., Märkl, B., Schwerer, M. J., Arndt, A., Kraft, K., Pröpper, C., & Möller, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040671 · Cited by 20
“Noteworthy, PI3K has already been shown to form a complex with Abi1, thus enhancing Rac activity [39,40,10].”
BackgroundCommon pathways for growth and for plasticity
Knafo, S., & Esteban, J. A. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.02.008 · Cited by 25
“Ras is a central signaling hub for the activation of many PI3K isoforms [33].”
BackgroundCaiola, E., Brunelli, L., Marabese, M., Broggini, M., Lupi, M., & Pastorelli, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9849 · Cited by 22
“KRAS signaling is highly complex and dynamic, engaging various downstream effectors, such as canonical Raf/Mek/Erk and PI3K/akt/mTOR signaling networks [9, 10].”
Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review
Acosta, A. M., & Kadkol, S. S. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0475-rs · Cited by 21
Mahmoud, N. N., Abuarqoub, D. A., Zaza, R., Sabbah, D. A., Khalil, E. A., & Abu‐Dahab, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093320 · Cited by 23
“Moreover, the inhibition of PI3k and its catalytic subunits upon treatment with the nanocomplex through the downregulation of the product genes PIK3CA, PIK3CB, PIK3CG, and PIK3CD, results in the dysregulation of the regulatory function of HRAS, which is responsible for regulating many cellular functions such as cell p…”
BackgroundUnraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer
Werle, S. D., Schwab, J. D., Tatura, M., Kirchhoff, S., Szekely, R., Diels, R., Ikonomi, N., Sipos, B., Sperveslage, J., Gress, T. M., et al. (2021) · Cancers · doi:10.3390/cancers13040725 · Cited by 25
Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development
Mohamad, T., Plante, C., & Brosseau, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168620 · Cited by 21
“RAS proteins are core regulators of cellular signaling because of their crossroad position with many signal transduction pathways and are highly conserved across species [78,79].”
BackgroundDowd, G. C., Bhalla, M., Kean, B., Thomas, R. R., & Ireton, K. (2016) · Infection and Immunity · doi:10.1128/iai.00142-16 · Cited by 22
“Some of these proteins, including Ras GTPases and PTK2/FAK, act upstream to control p110 catalytic activity (52, 53).”
BackgroundCirculating tumour DNA in B‐cell lymphomas: current state and future prospects
Lakhotia, R., & Roschewski, M. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17251 · Cited by 21
Targeting Oral Cancer: In Silico Docking Studies of Phytochemicals on Oncogenic Molecular Markers
Priyadarshini, G., Gheena, S., Dilipan, E., & Ramani, P. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.6.2069 · Cited by 29
“Research has demonstrated that in RAS mutant cell lines, PI3K signaling is necessary to sustain transformed growth [19].”
BackgroundSalmaninejad, A., Layeghi, S. M., Falakian, Z., Golestani, S., Kobravi, S., Talebi, S., & Yousefi, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01417-w · Cited by 25
“PI3K activation was also shown to enhance invasion by regulating the expression of various MMPs, like MMP2 in mouse mammary epithelial cells [111] or MMP9 in HT1080 cells [112, 113].”
BackgroundSakurai, A., Matsuda, M., & Kiyokawa, E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377804 · Cited by 20
“Requirement of PI3K for Preventing Apoptosis—The PI3K/ Akt pathway is best recognized as a regulator ofmammalian cell survival (29).”
BackgroundCalvo, I. F., Crespo, P., Santos, E., López-Novoa, J. M., & Martínez‐Salgado, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.07.008 · Cited by 21
Huang, F. H., Hu, X., Fang, C., Liu, H., Lin, C., Zhang, Y., & Hu, X. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1358-7 · Cited by 20
“Phosphatidylinositol-3-kinase (PI3K) activates phosphoinositide-dependent kinase 1 (PDK1) and AKT to promote cell cycle progression and cell survival (Castellano and Downward 2011; Li et al. 2014; Pacold et al. 2000).”
BackgroundMetabolism in Immune Cell Differentiation and Function
Chapman, N. M., Shrestha, S., & Chi, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_1 · Cited by 25
Dolgikh, N., Hugle, M., Vogler, M., & Fulda, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1737 · Cited by 23
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy
Nuryadi, E., Sasaki, Y., Hagiwara, Y., Permata, T. B. M., Sato, H., Komatsu, S., Yoshimoto, Y., Murata, K., Ando, K., Kubo, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25982 · Cited by 20
“In addition, amplification of PIK3CA and FGFR2 in T2 and T3, combined with activating mutations in KRAS and PIK3CA in T1−3, indicates a critical role for the RASPI3K axis in tumor survival through multiple rounds of radiotherapy [37].”
BackgroundOechsle, C. M., Showalter, L. E., Novak, C. M., Czerniecki, B. J., & Koski, G. K. (2020) · Vaccines · doi:10.3390/vaccines8010072 · Cited by 20
“…PBK / AKT intracellular signaling pathway also lies downstream of Ras, and promotes aspects of cell growth, survival, motility and resistance to apoptosis [48], we initially anticipated seeing attenuated phosphorylation in members of this pathway, owing to presumed losses in upstream Ras activity.”
Shafei, M. A., Forshaw, T. E., Davis, J., Flemban, A. F., Qualtrough, D., Dean, S., Perks, C. M., Dong, M., Newman, R. H., & Conway, M. E. (2020) · Oncotarget · doi:10.18632/oncotarget.27607 · Cited by 21
“It is known that Ras, which is activated with increased SOS, can also activate PI3K, Rac and Rho proteins associated with the regulation of the cytoskeleton and invasiveness of tumour cells [37].”
BackgroundThe mechanism of AKT activation in cancer
Meng, F., Li, H., Wang, Y., Zheng, Z., & Chen, Y. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100046 · Cited by 20
RAS pathway: The new frontier of brain mosaicism in epilepsy
Sran, S., & Bedrosian, T. A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106074 · Cited by 23
“Lastly, Ras can directly interact with p110 to trigger catalytic activation in a p85independent manner (Castellano and Downward, 2011).”
BackgroundExploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
“PIK3CA mutations activate the PI3K/AKT/mTOR pathway downstream of RAS activation, conferring resistance to anti-EGFR therapy in KRAS -wildtype mCRC, with a more pronounced effect in exon 20 alterations [103–105].”
BackgroundInhibition of Ras-mediated signaling pathways in CML stem cells
Bertacchini, J., Ketabchi, N., Mediani, L., Capitani, S., Marmiroli, S., & Saki, N. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0248-2 · Cited by 19
“hibition of PI3K and MEK might be effective in the treatment of the Ras-driven cancers [50].”
BackgroundRegulation of the CNC-bZIP transcription factor Nrf2 by Keap1 and the axis between GSK-3 and β-TrCP
Hayes, J. D., Ebisine, K., Sharma, R. S., Chowdhry, S., Dinkova‐Kostova, A. T., & Sutherland, C. D. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.10.003 · Cited by 21
“In the second mode of regulation (see upper right-hand half of cartoon) growth factors and somatic mutations causing activation of certain oncogenes, such as EGFR, HER2 and RAS, stimulate the PI3K pathway [22,23], which through activation of PKB/Akt results in inhibition of the constitutively active GSK-3 through phos…”
BackgroundCao, S., Aboelkassem, Y., Wang, A., Valdez‐Jasso, D., Saucerman, J. J., Omens, J. H., & McCulloch, A. D. (2020) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2019.0336 · Cited by 19
A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma
Eustace, N. J., Anderson, J. C., Warram, J. M., Widden, H., Pedersen, R. T., Alrefai, H., Patel, Z., Hicks, P. H., Placzek, W. J., Gillespie, G. Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01511-9 · Cited by 18
Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes
Hossain, M. T., & Hossain, M. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177432 · Cited by 23
Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 19
SWAN pathway-network identification of common aneuploidy-based oncogenic drivers
Bowers, R. R., Jones, C. M., Paz, E. A., Barrows, J. K., Armeson, K. E., Long, D. T., & Delaney, J. R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac200 · Cited by 24
“RAS mutation was associated with an increase in inositol phosphate mediated signaling (Figure 6C), likely increasing activation of PI3K (80).”
Anti-tumor potential and mode of action of karanjin against breast cancer; an in-silico approach
Dwivedi, P. S. R., & Shastry, C. S. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104778 · Cited by 19
Chen, X., Tang, G.-X., Dai, J., Dai, L.-T., Wu, T.-Y., Li, W., Ou, T., Huang, Z., Tan, J., & Chen, S.-B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00094 · Cited by 18
Lin, H.-J. L., Liu, Y., Caroland, K. P., & Lin, J. (2023) · Cancers · doi:10.3390/cancers15133507 · Cited by 22
“Mounting evidence demonstrates the critical role of PI3K being a regulator for embarking oncogenic KRAS-driven carcinogenesis, largely by governing cell survival and proliferation [26,27].”
BackgroundIbanez, K. R., Huang, T., & Lee, J.-M. (2024) · Cells · doi:10.3390/cells13121064 · Cited by 23
“In gynecological cancers, particularly OCs and ECs, the activation of the KRAS pathway and the presence of KRAS mutations are substantial factors contributing to both de novo and acquired resistance against PI3K pathway inhibitors [43] (Table 2).”
BackgroundTargeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling
Muratcioğlu, S., Aydın, C., Odabasi, E., Özdemir, E. S., Firat‐Karalar, E. N., Jang, H., Tsai, C., Nussinov, R., Kavaklı, İ. H., Gürsoy, A., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.002 · Cited by 19
Rahmani, F., Hashemzehi, M., Avan, A., Barneh, F., Asgharzadeh, F., Marjaneh, R. M., Soleimani, A., Parizadeh, M., Ferns, G. A., Mobarhan, M. G., et al. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110069 · Cited by 18
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin
Tervonen, T. A., Pant, S. M., Belitškin, D., Englund, J. I., Närhi, K. M., Haglund, C. H., Kovanen, P. E., Verschuren, E. W., & Klefström, J. T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1760 · Cited by 20
Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties
Li, Y., Wang, D., Ge, H., Güngör, C., Gong, X., & Chen, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15111369 · Cited by 18
Mohamed, E. E., Ahmed, O. M., Abdel‐Moneim, A., Zoheir, K. M. A., Elesawy, B. H., Askary, A., Hassaballa, A., & El‐Shahawy, A. A. G. (2022) · Pharmaceuticals · doi:10.3390/ph15121558 · Cited by 17
“Both HRAS and KRAS are frequently overexpressed in other cancer types as well [102].”
BackgroundHu, J., Fu, S., Zhan, Z., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116109 · Cited by 20
PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis
Yang, M., Lewińska, M., Fan, X., Zhu, J., & Yuan, Z.-M. (2016) · Oncogene · doi:10.1038/onc.2016.93 · Cited by 20
Jiang, M., Hua, Z., Dong, Y., Liu, Z., Thiele, C. J., & Li, Z. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.11.30 · Cited by 17
“Since the Ras signaling pathway is upstream of PI3K-Akt in the signaling pathway (32,33), we presumed that perifosine might also affect the upstream targets of Akt in NB.”
Chen, M.-W., Zhu, H., Xiong, C., Li, J., Zhao, L., Chen, H., & Qiu, Y. L. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00752-x · Cited by 19
Ganaie, A. A., Siddique, H. R., SHEIKH, I. A., Parray, A., Wang, L., Panyam, J., Villalta, P. W., Deng, Y., Konety, B. R., & Saleem, M. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23200 · Cited by 18
“These data are significant because activated Akt promotes tumor progression whereas Bcl2‐overexpression confers resistance to tumor cells.(23) Whereas lupeol caused a decrease in the phosphorylated‐ERK levels in lung and colon cancer cells, an inverse case was observed in PDAC cells (Figure 3E).”
BackgroundDai, B., Fan, M., Yu, R., Su, Q., Wang, B., Yang, T., Liu, F., & Zhang, Y. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.105000 · Cited by 17
Mutti, V., Bono, F., Tomasoni, Z., Bontempi, L., Guglielmi, A., Bolognin, S., Schwamborn, J. C., Missale, C., & Fiorentini, C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02748-z · Cited by 20
Jordán-Álvarez, S., Santana, E., Casas‐Tintó, S., Acebes, Á., & Ferrús, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184238 · Cited by 17
Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design
Haider, K., Sharma, A., Yar, M. S., Yakkala, P. A., Shafi, S., & Kamal, Ä. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2029842 · Cited by 17
“Constitutive PI3K activation resulting from the mutations in KRAS could lead to uncontrolled cell growth and oncogenic transformations [61].”
BackgroundPathania, A. S., Joshi, A., Kumar, S. G., Guru, S. K., Bhushan, S., Sharma, P. R., Bhat, W. W., Saxena, A. K., Singh, J., Shah, B. A., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0889-4 · Cited by 16
“Activating Ras mutations may upregulate these two pathways [29, 30] and thus, may promote cancer cell growth and proliferation.”
Stoy, C., Sundaram, A., García, M. R., Wang, X., Seibert, O., Zota, A., Wendler, S., Männle, D., Hinz, U., Sticht, C., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404837 · Cited by 18
“…triggers a number of downstream signaling pathways, including Raf/ MEK/ERK, RalGDS/p38 MAPK, Rac and Rho, and phosphatidyl-inositide 3 (PI3) kinase (Castellano & Downward, 2011), the latter of which seems to be responsible for the majority of KRAS-dependent pancreatic tumorigenesis (Eser et al ,…”
Kumar, D. T., Jain, N., Judith, E., Kamaraj, B., Ramamoorthy, S., Zayed, H., & Doss, C. G. P. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2019.103513 · Cited by 16
Diagnostic and therapeutic biomarkers in colorectal cancer: a review.
de Assis, J. V., Coutinho, L. A., Oyeyemi, I. T., Oyeyemi, O. T., & Grenfell, R. F. Q. (2022) · PubMed · Cited by 46
Nakhaei‐Rad, S., Nakhaeizadeh, H., Kordes, C., Cirstea, I. C., Schmick, M., Dvorský, R., Bastiaens, P. I. H., Häussinger, D., & Ahmadian, M. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.640607 · Cited by 16
Ren, J., Song, D., Bai, Q., Verkhratsky, A., & Peng, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00061 · Cited by 16
Koschut, D., Ray, D., Li, Z., Giarin, E., Groet, J., Alić, I., Kham, S. K. Y., Chng, W. J., Ariffin, H., Weinstock, D. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01567-7 · Cited by 15
Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination
Binamé, F., Pham-Van, L. D., & Bagnard, D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03852-4 · Cited by 16
Maadi, H., & Wang, Z. (2022) · Cells · doi:10.3390/cells11244093 · Cited by 21
Nasioudis, D., Llauradó, M., Wong, N. K. Y., Powell, D. J., Mills, G. B., Westin, S. N., Fader, A. N., Carey, M. S., & Simpkins, F. A. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.007 · Cited by 19
Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma
Estabrooks, T., Gurinovich, A., Pietruska, J. R., Lewis, B., Harvey, G., Post, G. S., Lambert, L., Miller, A., Rodrigues, L., White, M. E., et al. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12925 · Cited by 17
Li, M., Dai, L.-T., Gao, Z.-Y., Yan, J.-T., Xu, S., Tan, J., Huang, Z., Chen, S.-B., & Chen, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01773 · Cited by 17
PIN‐like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations
Kaur, H. B., Salles, D. C., Paulk, A., Epstein, J. I., Eshleman, J. R., & Lotan, T. L. (2020) · Histopathology · doi:10.1111/his.14224 · Cited by 15
“Similarly, cooperation of the PI3K and MAPK pathway activations in prostate cancer progression has also been characterised where prostate cancer in Pb-Cre, Pten, K-Ras mice displayed epithelial to mesenchymal transition (EMT) and metastatic phenotypes.(25) Another study looking at the genetic progression of high-grade…”
BackgroundRAS GTPase signalling to alternative effector pathways
Singh, S., & Smith, M. J. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200506 · Cited by 17
Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers
Singh, J., & Meena, A. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210909165426 · Cited by 17
Yellen, P., & Foster, D. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.027 · Cited by 17
“Despite intact PTEN, K-Ras-driven cancer cells can activate the PI3K/Akt pathway – making it difficult to target cancer cells harboring K-Ras mutations [18,19].”
BackgroundTargeting Ras with Macromolecules
Pei, D., Chen, K., & Liao, H. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031476 · Cited by 16
Khandakar, G. I., Satoh, R., Takasaki, T., Fujitani, K., Tanabe, G., Sakai, K., Nishio, K., & Sugiura, R. (2022) · Cells · doi:10.3390/cells11040702 · Cited by 17
EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis
Chen, D., Tang, Y., Lapinski, P. E., Wiggins, D., Sevick-Muraca, E. M., Davis, M. J., & King, P. D. (2024) · Circulation Research · doi:10.1161/circresaha.124.325383 · Cited by 17
“To confirm findings in HDLEC, we purified lung LEC from P14 control and EPHB4 2YP mice and examined MAPK activation in response to OSS in vitro (Figure 5E).”
InfluentialCholesterol metabolism in pancreatic cancer and associated therapeutic strategies
Daya, T., Breytenbach, A., Gu, L., & Kaur, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2024.159578 · Cited by 21
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.